Cerveau Technologies Inc. Signs Research Agreement with Takeda to Provide Novel Tau Imaging Agent

Friday, October 18, 2019

Cerveau Technologies, Inc. today announced a research collaboration agreement with Takeda Pharmaceutical Company Limited (Takeda), which will enable Takeda to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.

The collaboration is focused on using [F-18]MK-6240 as a biomarker in Takeda’s neurodegenerative disease research. The companies will evaluate Takeda’s investigational therapeutics for potential treatment of neurodegenerative diseases in humans.

“Cerveau is focused on enhancing access to key technologies that we believe have the potential to advance human health,” said Rick Hiatt, Chief Executive Officer, Cerveau Technologies, Inc. “We are excited to welcome Takeda to our growing network of pharmaceutical partners and global production sites. Our goal is to expand the availability of this novel investigational imaging agent to the broader scientific community.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc.

WE WELCOME YOUR VIEWS

Please enter your comment!
Please enter your name here